ATXS
Astria Therapeutics, Inc.Company Information
- Company Name
- Astria Therapeutics, Inc.
- CIK
- CIK0001454789
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ATXS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ATXS
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-02-01
- Last sale
- 2024-04-01
- Shares purchased (TTM)
- 4,295,958
- Shares sold (TTM)
- 19,200
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 51,535,959
- Shares outstanding
- 58,005,928
- Ownership
- 88.85%
Earnings Market Reaction
- Filing date
- 2025-11-12
- Price on filing date
- —
- 1-month reaction
- 3.03%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 96 | 76 | 54 | 60 | 81 | 87 | 172 | 176 | 120 | 134 | 202 | 21 | ||||||
| Short Term Investments | 131 | 183 | 241 | 268 | 263 | 267 | 198 | 71 | 69 | 69 | 11 | 206 | ||||||
| Accounts Receivable Net Current | 17 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 9 | 9 | 8 | 7 | 8 | 3 | 5 | 4 | 3 | 1 | 2 | 1 | ||||||
| Assets Current | 254 | 269 | 303 | 335 | 352 | 358 | 375 | 251 | 191 | 204 | 215 | 228 | ||||||
| Operating Lease Right Of Use Asset | 4 | 5 | 5 | 5 | 5 | 6 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 14 | 9 | 3 | 3 | 4 | 4 | 4 | 3 | 2 | 2 | 2 | 2 | ||||||
| Assets | 272 | 282 | 310 | 342 | 362 | 368 | 379 | 255 | 194 | 207 | 218 | 231 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 4 | 4 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 16 | 16 | 12 | 13 | 13 | 13 | 10 | 10 | 8 | 5 | 5 | 8 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Deferred Revenue Current | 4 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 24 | 18 | 17 | 19 | 16 | 16 | 11 | 12 | 9 | 7 | 7 | 9 | ||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 4 | 4 | 4 | 5 | - | - | - | 0 | 0 | 0 | ||||||
| Deferred Revenue Noncurrent | 12 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 39 | 21 | 21 | 23 | 20 | 21 | 11 | 12 | 9 | 7 | 7 | 9 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 911 | 907 | 902 | 899 | 895 | 876 | 873 | 728 | 638 | 636 | 635 | 633 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | -0 | 0 | 0 | 0 | -0 | -0 | - | - | - | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -773 | -742 | -709 | -675 | -649 | -625 | -600 | -581 | -549 | -531 | -519 | -508 | ||||||
| Stockholders Equity | 233 | 261 | 289 | 319 | 342 | 347 | 368 | 243 | 184 | 200 | 211 | 221 | ||||||
| Liabilities And Stockholders Equity | 272 | 282 | 310 | 342 | 362 | 368 | 379 | 255 | 194 | 207 | 218 | 231 | ||||||
| Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Nonredeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series X Redeemable Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 56 | 56 | 56 | 56 | 56 | 55 | 55 | 41 | 28 | 28 | 28 | 28 | ||||||
| Shares Outstanding | 56 | 56 | 56 | 56 | 56 | 55 | 55 | 41 | 28 | 28 | 28 | 28 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAstria Therapeutics, Inc. (ATXS) — SEC Financial Statements & Analysis
Astria Therapeutics, Inc. (ATXS) is a pharmaceutical preparations company, incorporated in DE. Astria Therapeutics, Inc. trades on Nasdaq as: ATXS. Astria Therapeutics, Inc. (ATXS)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-12. Based on that filing, On profitability, Astria Therapeutics, Inc. posts an operating margin of -19335.69%, a net margin of -17567.99%, a Return on Equity (ROE) of -43.15%, a Return on Assets (ROA) of -39.16%, and a Return on Invested Capital (ROIC) of -68.64%. Per share, it reports EPS of $-2.14, diluted EPS of $-2.14, free cash flow per share of $-2.07, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 23.98% year-over-year and EPS growth of 23.58% year-over-year. On the balance sheet, it maintains a current ratio of 10.78x, a quick ratio of 10.42x, working capital of $230.03M, a debt-to-equity ratio of 0.17x, a debt ratio of 0.14, free cash flow of $-120.32M (TTM), and net debt of $-96.28M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-2.14
- ROE TTM
- -43.15%
- ROA TTM
- -39.16%
- Debt To Equity
- 0.17x
- Free Cash Flow TTM
- $-120.32M
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Astria Therapeutics, Inc. in?
Astria Therapeutics, Inc. (ATXS) operates in the Pharmaceutical Preparations industry.
What exchange does ATXS trade on?
Astria Therapeutics, Inc. (ATXS) trades on the Nasdaq.
Where is Astria Therapeutics, Inc. incorporated?
Astria Therapeutics, Inc. is incorporated in DE.
When was Astria Therapeutics, Inc. (ATXS)'s most recent SEC filing?
Astria Therapeutics, Inc. (ATXS)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-12.
What is ATXS's EPS (earnings per share)?
Astria Therapeutics, Inc. (ATXS)'s trailing twelve month EPS is $-2.14 as of 2025-09-30.
What is ATXS's ROE (return on equity)?
Astria Therapeutics, Inc. (ATXS)'s trailing twelve month Return on Equity (ROE) is -43.15% as of 2025-09-30.
What is ATXS's ROA (return on assets)?
Astria Therapeutics, Inc. (ATXS)'s trailing twelve month Return on Assets (ROA) is -39.16% as of 2025-09-30.
What is ATXS's ROIC (return on invested capital)?
Astria Therapeutics, Inc. (ATXS)'s trailing twelve month Return on Invested Capital (ROIC) is -68.64% as of 2025-09-30.